Clinical Trials
3 trialsNCT01643603 2020-12-17
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01609816 2020-03-16
Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01092728 2016-09-05
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
M.D. Anderson Cancer Center
Phase 2 Terminated